Barclays Adjusts Elevance Health (ELV) PT to $393 While Maintaining Overweight Rating

Core Viewpoint - Elevance Health Inc. (NYSE:ELV) is considered one of the most undervalued large-cap stocks currently available for investment, despite recent adjustments in price targets by various analysts [1]. Analyst Ratings and Price Targets - Barclays has lowered its price target for Elevance Health to $393 from $404 while maintaining an Overweight rating [1]. - Guggenheim analyst Jason Cassorla has also reduced the price target to $396 from $414, keeping a Buy rating based on recalibrated 2026 estimates following the company's Q4 2025 report [1]. - Deutsche Bank raised its price target to $332 from $320, maintaining a Hold rating, suggesting that the company's 2026 outlook may represent a floor [2]. - UBS has lowered its price target to $400 from $425 while maintaining a Buy rating [3]. Company Overview - Elevance Health Inc. operates as a health benefits company in the US, with four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other [3].